Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib versus paclitaxel or irinotecan as second-line treatment for advanced gastric cancer
CTR20200708Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2020; status: active.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200708.